Objective:To explore the effect of selenium supplementation on thyroid function, immune response and oxidative stress in HT patients with normal thyroid function.Methods: A total of 120 Hashimoto's thyroiditis pat...Objective:To explore the effect of selenium supplementation on thyroid function, immune response and oxidative stress in HT patients with normal thyroid function.Methods: A total of 120 Hashimoto's thyroiditis patients with normal thyroid function admitted to our hospital from June 2016 to March 2018 were randomly divided into treatment group and control group with 60 cases in each group. The control group was given oral placebo, while the treatment group was given selenium yeast. The expression levels of thyroid function [including thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)], immune response [including thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb), interferon-γ (IFN-γ), interleukin-4 (IL-4)] and oxidative stress [including malondialdehyde (MDA), glutathione peroxidase (GPx) and superoxide dismutase (SOD)] were observed and compared between the two groups.Results: The two groups showed significant changes in auxiliary diagnosis, immune response and oxidative stress. Before treatment, there was no significant difference in the levels between the two groups. After treatment, there was no significant difference in the above indexes between the control group and that before treatment. There was no significant difference in thyroid function related indexes between the treatment group and the control group. The levels of TPOAb, TGAb, IFN-γ and MDA in the treatment group were significantly lower than those before treatment and in the control group, while the levels of IL-4, GPx and SOD were significantly higher than those before treatment and in the control group.Conclusions: Selenium supplementation can stabilize thyroid function, reduce the level of thyroid antibody production, and improve immune response and oxidative stress response in HT patients.展开更多
目的:探讨上消化道晚期肿瘤患者在接受免疫治疗后,发生甲状腺功能异常(thyroid function abnormality,TFA)的临床特征、影响因素以及其与疗效的相关性。方法:回顾性收集2019年1月至2024年4月就诊于新疆医科大学第一附属医院接受免疫治疗...目的:探讨上消化道晚期肿瘤患者在接受免疫治疗后,发生甲状腺功能异常(thyroid function abnormality,TFA)的临床特征、影响因素以及其与疗效的相关性。方法:回顾性收集2019年1月至2024年4月就诊于新疆医科大学第一附属医院接受免疫治疗的102例上消化道晚期肿瘤患者的临床资料,根据甲状腺功能分为TFA组与正常组,应用χ^(2)检验及多因素Logistic回归探究TFA发生的影响因素。应用单因素及多因素Cox回归分析、绘制Kaplan-Meier曲线探究TFA与疗效的相关性。结果:102例接受免疫治疗的上消化道晚期肿瘤患者中,有43例(38.23%)患者发生TFA,其发生TFA的中位时间为5.36个月。多因素Logistic回归分析发现肝转移、既往联合治疗方案数、癌胚抗原(CEA)是TFA发生的影响因素(P<0.05)。TFA组的客观缓解率(objective response rate,ORR)(39.53%vs.6.78%,P<0.001)和疾病控制率(disease control rate,DCR)(72.09%vs.35.59%,P<0.001)均优于正常组。Cox回归分析示TFA是疗效的影响因素(P<0.05);TFA组患者相比于甲状腺功能正常组患者的1年生存率显著延长(90.70%vs.79.66%)。结论:肝转移、既往联合治疗方案数、CEA可能是TFA发生的影响因素,TFA可能是免疫治疗疗效的预测因子,对于接受免疫治疗的上消化道晚期肿瘤患者,出现TFA可能预示着更好的治疗效果。展开更多
文摘Objective:To explore the effect of selenium supplementation on thyroid function, immune response and oxidative stress in HT patients with normal thyroid function.Methods: A total of 120 Hashimoto's thyroiditis patients with normal thyroid function admitted to our hospital from June 2016 to March 2018 were randomly divided into treatment group and control group with 60 cases in each group. The control group was given oral placebo, while the treatment group was given selenium yeast. The expression levels of thyroid function [including thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)], immune response [including thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb), interferon-γ (IFN-γ), interleukin-4 (IL-4)] and oxidative stress [including malondialdehyde (MDA), glutathione peroxidase (GPx) and superoxide dismutase (SOD)] were observed and compared between the two groups.Results: The two groups showed significant changes in auxiliary diagnosis, immune response and oxidative stress. Before treatment, there was no significant difference in the levels between the two groups. After treatment, there was no significant difference in the above indexes between the control group and that before treatment. There was no significant difference in thyroid function related indexes between the treatment group and the control group. The levels of TPOAb, TGAb, IFN-γ and MDA in the treatment group were significantly lower than those before treatment and in the control group, while the levels of IL-4, GPx and SOD were significantly higher than those before treatment and in the control group.Conclusions: Selenium supplementation can stabilize thyroid function, reduce the level of thyroid antibody production, and improve immune response and oxidative stress response in HT patients.
文摘目的:探讨上消化道晚期肿瘤患者在接受免疫治疗后,发生甲状腺功能异常(thyroid function abnormality,TFA)的临床特征、影响因素以及其与疗效的相关性。方法:回顾性收集2019年1月至2024年4月就诊于新疆医科大学第一附属医院接受免疫治疗的102例上消化道晚期肿瘤患者的临床资料,根据甲状腺功能分为TFA组与正常组,应用χ^(2)检验及多因素Logistic回归探究TFA发生的影响因素。应用单因素及多因素Cox回归分析、绘制Kaplan-Meier曲线探究TFA与疗效的相关性。结果:102例接受免疫治疗的上消化道晚期肿瘤患者中,有43例(38.23%)患者发生TFA,其发生TFA的中位时间为5.36个月。多因素Logistic回归分析发现肝转移、既往联合治疗方案数、癌胚抗原(CEA)是TFA发生的影响因素(P<0.05)。TFA组的客观缓解率(objective response rate,ORR)(39.53%vs.6.78%,P<0.001)和疾病控制率(disease control rate,DCR)(72.09%vs.35.59%,P<0.001)均优于正常组。Cox回归分析示TFA是疗效的影响因素(P<0.05);TFA组患者相比于甲状腺功能正常组患者的1年生存率显著延长(90.70%vs.79.66%)。结论:肝转移、既往联合治疗方案数、CEA可能是TFA发生的影响因素,TFA可能是免疫治疗疗效的预测因子,对于接受免疫治疗的上消化道晚期肿瘤患者,出现TFA可能预示着更好的治疗效果。
